NCT02472548View on ClinicalTrials.gov

A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 14, 2017

Study Completion Date

March 14, 2017

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

DPX-RSV(A)

Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

BIOLOGICAL

RSV(A)-Alum

Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.

OTHER

Placebo

Normal saline (0.9 % sodium chloride) will be administered intramuscularly.

Trial Locations (1)

B3K 6R8

IWK Health Centre, Halifax

All Listed Sponsors
collaborator

ImmunoVaccine Technologies, Inc. (IMV Inc.)

INDUSTRY

lead

Dalhousie University

OTHER

NCT02472548 - A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine | Biotech Hunter | Biotech Hunter